Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CDA | P32320 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine SCHEMBL471171 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL12202579 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL329878 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL172274 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14644972 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14853684 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL15630291 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019024784-A1 | FATTY ACID CONJUGATED NANOPARTICLES AND USES THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-02-07 | — | — | WO | claimed |
| US-20190029970-A1 | FATTY ACID CONJUGATED NANOPARTICLES AND USES THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-01-31 | — | — | US | claimed |
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | claimed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | claimed |
| US-20240180962-A1 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | GC Cell Corporation (KR) | 2024-06-06 | — | — | US | disclosed |
| US-20240141436-A1 | Compounds, Compositions and Methods of Treatment Thereof | iTeos Belgium SA (BE) | 2024-05-02 | — | — | US | disclosed |
| US-11945877-B2 | Anti-HER2 antibodies | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-04-02 | — | — | US | disclosed |
| EP-4319769-A1 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | Artiva Biotherapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11896634-B2 | Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-13 | — | — | US | disclosed |
| CN-112516071-B | Injection preparation of 3-boric acid phenyl-1-carbamic acid cholesterol ester and preparation method thereof | 南京大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20240000840-A1 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | GC Cell Corporation (KR) | 2024-01-04 | — | — | US | disclosed |
| EP-4285914-A2 | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY | Baylor College of Medicine (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2002096400-A1 | MEDICAMENT WHICH CAN BE USED FOR THE TREATMENT OF CANCER | MOLECULAR ENGINES LABORATORIES (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2001097844-A1 | BISPECIFIC FUSION PROTEIN AND METHOD OF USE FOR ENHANCING EFFECTOR CELL KILLING OF TARGET CELLS | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-12-27 | — | — | WO | disclosed |
| CN-1316055-A | Differential diagnosis of neurodegeneration | INNOGENETICS NV (BE) | 2001-10-03 | — | — | CN | disclosed |
| EP-1030839-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024401-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5641758-A | 4-OCTADECYLAMINO-1-ARABINOFURANOSYL-2-PYRIMIDINONE ANTITUMOR AGENTS | KLUGE MICHAEL (DE) | 1997-06-24 | — | — | US | disclosed |
| US-5437600-A | Method and apparatus for the treatment of cancer | LIFE RESONANCES, INC. (US) | 1995-08-01 | — | — | US | disclosed |
| US-5045050-A | Method and apparatus for the treatment of cancer | LIFE RESONANCES (US) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240141436-A1 | Compounds, Compositions and Methods of Treatment Thereof | ADORA2A, ADORA2B, ADORA3 | LMNA 2110/4885MTOR 2181/4885THRB 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.